MXPA03002413A - Moleculas tipo b7 y uso de las mismas. - Google Patents

Moleculas tipo b7 y uso de las mismas.

Info

Publication number: MXPA03002413A
Authority: MX; Mexico
Prior art keywords: polypeptides; methods; provides; molecules; amelioration
Prior art date: 2000-09-20

Application number

MXPA03002413A

Other languages

English (en)

Inventor

Steven Kiyoshi Yoshinaga

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-20

Filing date

2001-09-19

Publication date

2003-06-19

2001-09-19 Application filed by Amgen Inc filed Critical Amgen Inc

2003-06-19 Publication of MXPA03002413A publication Critical patent/MXPA03002413A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Biophysics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)

MXPA03002413A 2000-09-20 2001-09-19 Moleculas tipo b7 y uso de las mismas. MXPA03002413A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23386700P	2000-09-20	2000-09-20
PCT/US2001/029183 WO2002024891A2 (en)	2000-09-20	2001-09-19	B7-like molecules and uses thereof

Publications (1)

Publication Number	Publication Date
MXPA03002413A true MXPA03002413A (es)	2003-06-19

Family

ID=22878998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03002413A MXPA03002413A (es)	2000-09-20	2001-09-19	Moleculas tipo b7 y uso de las mismas.

Country Status (9)

Country	Link
US (3)	US20020107363A1 (es)
EP (1)	EP1328624B1 (es)
JP (2)	JP4584536B2 (es)
AT (1)	ATE532860T1 (es)
AU (1)	AU2001291087A1 (es)
CA (1)	CA2422215A1 (es)
ES (1)	ES2372522T3 (es)
MX (1)	MXPA03002413A (es)
WO (1)	WO2002024891A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3016482A1 (en) *	1999-11-30	2001-06-07	Mayo Foundation For Medical Education And Research	B7-h1, a novel immunoregulatory molecule
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
CA2412377A1 (en)	2000-06-06	2001-12-13	Bristol-Myers Squibb Company	B7-related nucleic acids and polypeptides and their uses for immunomodulation
JP4584536B2 (ja) *	2000-09-20	2010-11-24	アムジェンインコーポレイテッド	Ｂ７様分子およびその使用
US7794710B2 (en) *	2001-04-20	2010-09-14	Mayo Foundation For Medical Education And Research	Methods of enhancing T cell responsiveness
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
MXPA05006535A (es) *	2002-12-23	2005-09-08	Immunex Corp	Acidos nucleicos, proteinas y anticuerpos btl-ii.
MX2007004176A (es)	2004-10-06	2007-06-15	Mayo Foundation	B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
DK1907000T4 (da)	2005-06-08	2020-03-30	The President And Fellows Of Harvard College	Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
US20090215084A1 (en) *	2006-01-05	2009-08-27	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
WO2007082144A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and survivin in cancer
US20100075377A1 (en) *	2006-04-13	2010-03-25	West James W	Tetramerizing polypeptides and methods of use
EP2004682A2 (en) *	2006-04-13	2008-12-24	Zymogenetics, Inc.	Tetramerizing polypeptides and methods of use
EP2007806A2 (en) *	2006-04-13	2008-12-31	ZymoGenetics, Inc.	Tetramerizing polypeptides and methods of use
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
US20100035973A1 (en) *	2006-07-17	2010-02-11	Nationwide Children's Hospital, Inc.	Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines
AU2007339897B2 (en)	2006-12-27	2013-02-14	Dana-Farber Cancer Institute, Inc.	Compositions and methods for the treatment of infections and tumors
FI119513B (fi) *	2007-03-07	2008-12-15	Dextech Medical Ab	Muokatut hydroksipolymeerikonjugaatit, joilla on tappava vaikutus tuumorisoluihin
CA2693707A1 (en)	2007-07-13	2009-03-05	The Johns Hopkins University	B7-dc variants
WO2009097017A2 (en) *	2007-09-18	2009-08-06	The Jackson Laboratory	Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
WO2009111315A2 (en) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Methods for reducing granulomatous inflammation
EP2328919A2 (en) *	2008-08-25	2011-06-08	Amplimmune, Inc.	Pd-i antagonists and methods for treating infectious disease
PL2350129T3 (pl)	2008-08-25	2015-12-31	Amplimmune Inc	Kompozycje antagonistów PD-1 i sposoby stosowania
EP2370593B1 (en) *	2008-11-28	2016-03-30	Emory University	Methods for determining the efficacy of pd-1 antagonists
EP4331604B9 (en)	2008-12-09	2025-07-23	F. Hoffmann-La Roche AG	Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011127418A1 (en)	2010-04-09	2011-10-13	Amgen Inc.	Btnl9 proteins, nucleic acids, and antibodies and uses thereof
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
US10259875B2 (en)	2013-10-01	2019-04-16	Mayo Foundation For Medical Education And Research	Methods for treating cancer in patients with elevated levels of BIM
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt)	2014-03-14	2020-02-10	Novartis Ag	Antikūno molekulės prieš lag-3 ir jų panaudojimas
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2016014148A1 (en)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Targeting dna-pkcs and b7-h1 to treat cancer
CA2960824A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of alk inhibitors
JP6877339B2 (ja)	2014-10-14	2021-05-26	ノバルティスアーゲー	Ｐｄ−ｌ１に対する抗体分子およびその使用
AU2016291817A1 (en)	2015-07-16	2018-02-22	Biolinerx Ltd.	Compositions and methods for treating cancer
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
WO2017165412A2 (en)	2016-03-21	2017-09-28	Dana-Farber Cancer Institute, Inc.	T-cell exhaustion state-specific gene expression regulators and uses thereof
US11572541B2 (en)	2017-06-09	2023-02-07	Providence Health & Services—Oregon	Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
EP3873540A4 (en)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
AU2022288058A1 (en)	2021-06-07	2023-11-16	Agonox, Inc.	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5328470A (en) *	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO2001034629A1 (en) *	1999-11-12	2001-05-17	Human Genome Sciences, Inc.	21 human secreted proteins
US6468546B1 (en)	1998-12-17	2002-10-22	Corixa Corporation	Compositions and methods for therapy and diagnosis of ovarian cancer
WO2000055375A1 (en) *	1999-03-17	2000-09-21	Alphagene, Inc.	Secreted proteins and polynucleotides encoding them
ATE399793T1 (de) *	1999-04-02	2008-07-15	Corixa Corp	Verbindungen und verfahren für therapie und diagnose von lungenkrebs
JP2002171977A (ja) *	1999-07-29	2002-06-18	Herikkusu Kenkyusho:Kk	新規なヒトｓｈ２蛋白質
EP1074617A3 (en) *	1999-07-29	2004-04-21	Research Association for Biotechnology	Primers for synthesising full-length cDNA and their use
ES2281362T3 (es)	1999-11-12	2007-10-01	Bridgestone Corporation	Polimeros modificados preparados con catalizadores basados en lantanidos.
CA2412377A1 (en) *	2000-06-06	2001-12-13	Bristol-Myers Squibb Company	B7-related nucleic acids and polypeptides and their uses for immunomodulation
AU2001273096B8 (en) *	2000-06-28	2005-10-13	Dana-Farber Cancer Institute, Inc.	PD-L2 molecules: novel PD-1 ligands and uses therefor
AU2001271714A1 (en) *	2000-06-30	2002-01-14	Human Genome Sciences, Inc.	B7-like polynucleotides, polypeptides, and antibodies
US6635750B1 (en) *	2000-07-20	2003-10-21	Millennium Pharmaceuticals, Inc.	B7-H2 nucleic acids, members of the B7 family
JP4584536B2 (ja) *	2000-09-20	2010-11-24	アムジェンインコーポレイテッド	Ｂ７様分子およびその使用

2001
- 2001-09-19 JP JP2002529486A patent/JP4584536B2/ja not_active Expired - Fee Related
- 2001-09-19 US US09/955,866 patent/US20020107363A1/en not_active Abandoned
- 2001-09-19 ES ES01971167T patent/ES2372522T3/es not_active Expired - Lifetime
- 2001-09-19 MX MXPA03002413A patent/MXPA03002413A/es active IP Right Grant
- 2001-09-19 AU AU2001291087A patent/AU2001291087A1/en not_active Abandoned
- 2001-09-19 CA CA002422215A patent/CA2422215A1/en not_active Abandoned
- 2001-09-19 AT AT01971167T patent/ATE532860T1/de active
- 2001-09-19 EP EP01971167A patent/EP1328624B1/en not_active Expired - Lifetime
- 2001-09-19 WO PCT/US2001/029183 patent/WO2002024891A2/en not_active Ceased
2004
- 2004-11-29 US US10/998,526 patent/US7414122B2/en not_active Expired - Fee Related
2008
- 2008-04-22 JP JP2008111908A patent/JP4792057B2/ja not_active Expired - Fee Related
- 2008-06-27 US US12/163,258 patent/US20090004237A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP4792057B2 (ja)	2011-10-12
US20020107363A1 (en)	2002-08-08
AU2001291087A1 (en)	2002-04-02
WO2002024891A9 (en)	2003-11-06
EP1328624B1 (en)	2011-11-09
CA2422215A1 (en)	2002-03-28
US20050228170A1 (en)	2005-10-13
WO2002024891A2 (en)	2002-03-28
JP2008263984A (ja)	2008-11-06
EP1328624A2 (en)	2003-07-23
ES2372522T3 (es)	2012-01-23
US7414122B2 (en)	2008-08-19
JP2004523215A (ja)	2004-08-05
ATE532860T1 (de)	2011-11-15
WO2002024891A3 (en)	2003-04-17
JP4584536B2 (ja)	2010-11-24
US20090004237A1 (en)	2009-01-01

Publication	Publication Date	Title
MXPA03002413A (es)	2003-06-19	Moleculas tipo b7 y uso de las mismas.
WO2002002624A3 (en)	2002-07-04	B7-like molecules and uses thereof
WO2001070977A3 (en)	2002-03-28	Fibroblast growth factor receptor-like molecules and uses thereof
WO2001092308A3 (en)	2002-04-11	Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
MXPA02012743A (es)	2003-04-25	Moleculas tipo il-17 y usos de las mismas.
AU8881201A (en)	2002-03-22	Tnf receptor-like molecules and uses thereof
WO2002000724A3 (en)	2003-01-03	Thymic stromal lymphopoietin receptor molecules and uses thereof
WO2001061007A3 (en)	2002-03-14	Fibroblast growth factor-23 molecules and uses thereof
WO2001068854A3 (en)	2002-03-21	Fibroblast growth factor-like molecules and uses thereof
WO2001068859A3 (en)	2002-03-21	Il-17 receptor like molecules and uses thereof
WO2001068705A3 (en)	2002-07-18	Il-17 receptor like molecules and uses thereof
TW200640944A (en)	2006-12-01	VGF polypeptides and methods of treating VGF-related disorders
WO2003024991A3 (en)	2003-10-02	Tall-1 receptor molecules and uses thereof
WO2000053776A3 (en)	2000-12-14	Human kallikrein-like genes
WO2001042474A3 (en)	2002-02-28	Interferon-like molecules and uses thereof
WO2003087338A3 (en)	2006-01-05	Her-2 receptor tyrosine kinase molecules and uses thereof
MXPA03000979A (es)	2004-08-12	Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
WO2002000723A3 (en)	2002-05-30	Thymic stromal lymphopoietin receptor molecules and uses thereof
MXPA03010728A (es)	2004-03-02	Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
MXPA02000680A (es)	2002-07-02	Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
PL374550A1 (en)	2005-10-31	Il-17 like molecules and uses thereof
WO2002083736A3 (en)	2003-11-20	G-protein coupled receptor molecules and uses thereof
WO2001074903A3 (en)	2002-08-22	Cd20/ige-receptor like molecules and uses thereof
WO2002014489A3 (en)	2002-07-25	Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
WO2002044379A3 (en)	2003-03-13	Transforming growth factor-beta-related molecules and uses thereof

Legal Events

Date	Code	Title	Description
2009-11-23	FG	Grant or registration